SURVYR

OCUL

Ocular Therapeutix, Inc.
$6.47
−$0.03 (0.46%)Oct 26 close
Biotech & HealthcareSP500 CompareTechnicals
1M3M6M1Y2Y
-48%-25%-3%+20%+42%Oct 2025Oct 2026Apr 202652w high $16.4452w low $6.00
OCULSPY
Wall St. Highest PT $34.00 (+425.5%) Wall St. Avg PT $25.45 (+293.4%)
$6$16$26$36$47POC $9Hi $34Avg $25
Underwater Drawdown %Max DD -61.0%Current -59.8%
0.0%-61.0%
Relative Strength vs SPY-56.9% vs SPYUnderperforming
+67%0%-67%
1W
+$0.18 (2.86%)
1M
−$3.18 (32.95%)
3M
−$2.17 (25.12%)
6M
−$3.05 (32.04%)
YTD
−$5.67 (46.71%)
1Y
−$5.02 (43.69%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
11 analysts · mean score 1.33
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$6.47
Average target$25.45
+$18.98 (+293.4%) upsideaverage target vs current price
CurrentAverageMedian
Low$14.00
Median$25.45
High$34.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-19 · Needham reiterated Buy on OCUL
Initiated
2026-10-12 · UBS started covering OCUL at Buy
Reiterated
2026-10-02 · Chardan Capital reiterated Buy on OCUL
Reiterated
2026-09-29 · Needham reiterated Buy on OCUL
Reiterated
2026-09-16 · Chardan Capital reiterated Buy on OCUL
Reiterated
2026-09-16 · HC Wainwright & Co. reiterated Buy on OCUL
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$1.4B
P/E (next 12 months, estimated)-4.4
52-week range$6.00 – $16.44
Revenue growth (latest quarter vs a year ago)+0.1%
Dividend yieldNo dividend
Analyst consensusStrong Buy (11)
Average analyst price target$25.45 (+293%)

What they do

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for OCUL yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Held by 1 of 7 live models: SURVYR. Barbell Momentum & T-Bill Shield.

SURVYR. Barbell Momentum & T-Bill Shield
5.0% of the book · Mid-Cap RS & EPS Leaders (75%) sleeve · ranked 16 of 160
 HeldQuality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book
Why it's in the SURVYR. Barbell Momentum & T-Bill Shield #16 of 160

Qualified on SOL-1 superiority readout + multi-billion retina franchise potential. Ranked 16th of 160 at the 2026-10-01 rebalance.

What would knock it out: Drops out if it falls outside the top 16 at the next rebalance (Oct 30).

Earnings & events

OCUL earningsNext report in 8 days
Next report
Wed Nov 4, 2026Before the open
EPS consensus-$0.35 range -$0.37–-$0.30
Revenue consensus$14.3M 12 analysts
Last 4 quarters · EPS vs estimate
Aug 3, 2026-$0.35est -$0.39+9.4%Above estimates
May 5, 2026-$0.40est -$0.31−27.6%Below estimates
Feb 5, 2026-$0.29est -$0.34+13.9%Above estimates
Nov 4, 2025-$0.38est -$0.35−9.6%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-23 23:31:00 ET
24-1125-0325-0525-0825-1126-0226-0526-08-0.400.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$13.5M+0.1%
2026-03-31$10.8M–
2025-12-31$13.2M–
2025-09-30$14.5M–
2025-06-30$13.5M–

News & catalysts

More news
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win
MarketBeat · Oct 20
Ocular Therapeutix Has 75% Success Probability for Axpaxli in Wet Age-Related Macular Degeneration, UBS Says
MT Newswires · Oct 20
Novavax, Ocular Therapeutix, and QuidelOrtho Shares Plummet, What You Need To Know
StockStory · Oct 16
1 Russell 2000 Stock with Solid Fundamentals and 2 We Avoid
StockStory · Oct 15
3 Healthcare Stocks We Find Risky
StockStory · Oct 13
Rating changes
Reiterated
2026-10-19 · Needham reiterated Buy on OCUL
Initiated
2026-10-12 · UBS started covering OCUL at Buy
Reiterated
2026-10-02 · Chardan Capital reiterated Buy on OCUL
Reiterated
2026-09-29 · Needham reiterated Buy on OCUL
Reiterated
2026-09-16 · Chardan Capital reiterated Buy on OCUL
Reiterated
2026-09-16 · HC Wainwright & Co. reiterated Buy on OCUL

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Anderman Todd
Chief Legal Officer · 2026-10-08
Sell
$87.4K
Heier Jeffrey S.
Chief Scientific Officer · 2026-10-02
Sell
$76.6K
Kaiser Peter
Chief Development Officer · 2026-10-02
Sell
$70.4K
Notman Donald
Chief Operating Officer · 2026-08-31
Sell
$11.3K
Dugel Pravin
Director, See Remarks · 2026-08-24
Sell
$233.2K
Heier Jeffrey S.
Chief Scientific Officer · 2026-08-24
Sell
$35.5K
Nayak Sanjay
Chief Strategy Officer · 2026-08-24
Sell
$20.4K
Kaiser Peter
Chief Development Officer · 2026-08-24
Sell
$32.7K

Stats refreshed 2026-10-23 23:31:00 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026